CompletedInterventionalPhase 2Updated Nov 15, 2013
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis | NCT00380783 | Trialant
TerminatedInterventionalPhase 2Updated May 30, 2011
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
ClinicalTrials.gov ID
NCT00380783
Lead Sponsor
AllerganINDUSTRY
Overall Status
Terminated
Study Type
Interventional
Phase
Phase 2
Enrollment
2Actual
Last Update Posted
May 30, 2011Estimated
Start Date
Oct 2006
Primary Completion Date
Mar 2007Actual
Completion Date
Mar 2007Actual
Brief Summary
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis
Cystitis, Interstitial
AGN 203818
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
Female
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of painful bladder syndrome/interstitial cystitis